Altimmune (ALT) Reiterated at Market Outperform By Citizens After EASL Presentation

June 2, 2026 4:28 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $11.00 price target on Altimmune (NASDAQ: ALT).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found